Cepi and moderna harness mrna technology to advance 100 days mission

New partnership will harness moderna's mrna rapid-response platform, clinically validated during the covid-19 pandemic, to accelerate epidemic and pandemic vaccine development first project will enable rapid pre-clinical testing of antigen designs for high-risk viral families, to advance global outbreak readiness cambridge, ma / accesswire / october 30, 2023 / the coalition for epidemic preparedness innovations (cepi) and moderna, inc. (nasdaq:mrna) have entered into a strategic partnership that will harness moderna's mrna platform to accelerate the development of vaccines against viral disease outbreaks that threaten global health. the work undertaken as part of this partnership could expand the infectious disease targets for mrna vaccine technology and strengthen pandemic preparedness and public health efforts in alignment with the 100 days mission , a global goal to compress vaccine development timelines to 100 days.
MRNA Ratings Summary
MRNA Quant Ranking